![Healthcare reform in the United States / Presidency of Lyndon B. Johnson / Myelodysplastic syndrome / Syndromes / Erythropoietin / Medicare / Lenalidomide / Medicaid / National coverage determination / Medicine / Health / Federal assistance in the United States Healthcare reform in the United States / Presidency of Lyndon B. Johnson / Myelodysplastic syndrome / Syndromes / Erythropoietin / Medicare / Lenalidomide / Medicaid / National coverage determination / Medicine / Health / Federal assistance in the United States](https://www.pdfsearch.io/img/16a63ea162c4f0f887aa2a2db0477c58.jpg) Date: 2014-12-24 12:13:32Healthcare reform in the United States Presidency of Lyndon B. Johnson Myelodysplastic syndrome Syndromes Erythropoietin Medicare Lenalidomide Medicaid National coverage determination Medicine Health Federal assistance in the United States | | 2014: Volume 4, Number 4 A publication of the Centers for Medicare & Medicaid Services, Office of Information Products & Data Analytics Effect of Erythropoiesis-Stimulating Agent Policy Decisions on Off-Label Use inAdd to Reading ListSource URL: cms.govDownload Document from Source Website File Size: 804,16 KBShare Document on Facebook
|